Primary endoscopic interventions in bariatric surgery

Abstract

The global prevalence of obesity [body mass index (BMI) ≥ 30 kg/m²] was estimated to affect nearly 890 million adults in 2022, with increasing rates in both adults and children. While comprehensive lifestyle management (diet, exercise, behavioral modification) and pharmacotherapy are central to obesity treatment, metabolic bariatric surgery (MBS), such as sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB), remains the most effective and durable approach for obesity and obesity-related comorbidities, including hypertension, type 2 diabetes, and cardiovascular disease. Despite its effectiveness, MBS is significantly underutilized due to multiple barriers such as the risk of surgery, access limitations, prohibitive social factors, the perceived need for surgery, and fear and beliefs about surgery. Endoscopic bariatric and metabolic therapies (EBMTs) have emerged as an alternative approach to address this gap. While EBMTs are less invasive and have fewer complications than MBS, they are also less effective, though more effective than lifestyle modifications and pharmacotherapy alone. EBMTs, including procedures that involve gastric volume reduction through gastric remodeling or space-occupying devices, malabsorption, or caloric intake reduction, are recommended by the American Society for Gastrointestinal Endoscopy (ASGE) and American Society of Metabolic and Bariatric Surgery (ASMBS) for patients who have not succeeded with lifestyle changes or medications, and as bridge therapies for patients who require weight loss for additional medical treatments. Although EBMTs do not replace bariatric surgery, they complement the existing treatment options, offering patients a less invasive pathway to weight loss and improved metabolic health. Reimbursement models for physicians and the associated financial cost of EBMTs may present inherent complexities. Nevertheless, the prospect of enhanced patient outcomes, substantial reductions in long-term healthcare costs, and expansion of insurance coverage to include these procedures collectively foster optimism for the wider integration of these innovative therapies into clinical practice.

Keywords

Endoscopic bariatric and metabolic therapies / endoscopic sleeve gastroplasty / primary obesity surgery endoluminal / intragastric balloons / incisionless magnetic anastomosis system / magnetic system

References

[1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.Lancet2024;403:1027-50 PMCID:PMC7615769

[2] Pipek LZ,Nobetani RM.Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis.Sci Rep2024;14:9521 PMCID:PMC11045962

[3] Courcoulas AP,Hu B.Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes.JAMA2024;331:654-64 PMCID:PMC10900968

[4] Martin M,Kjorstad R.Socioeconomic disparities in eligibility and access to bariatric surgery: a national population-based analysis.Surg Obes Relat Dis2010;6:8-15

[5] Chang SH,Song J,Eagon CJ.The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012.JAMA Surg2014;149:275-87 PMCID:PMC3962512

[6] Longitudinal Assessment of Bariatric Surgery (LABS) Consortium; Flum DR, Belle SH, King WC, et al. Perioperative safety in the longitudinal assessment of bariatric surgery.N Engl J Med2009;361:445-54 PMCID:PMC2854565

[7] ASGE Bariatric Endoscopy Task Force; Sullivan S, Kumar N, Edmundowicz SA, et al. ASGE position statement on endoscopic bariatric therapies in clinical practice.Gastrointest Endosc2015;82:767-72

[8] Imbus JR,Funk LM.Bariatric surgery barriers: a review using Andersen’s Model of Health Services Use.Surg Obes Relat Dis2017;14:404-12 PMCID:PMC6039385

[9] Král J,Horká V.Endoscopic treatment of obesity and nutritional aspects of bariatric endoscopy.Nutrients2021;13:4268 PMCID:PMC8703836

[10] Jung SH,Choi HS.Comparative efficacy of bariatric endoscopic procedures in the treatment of morbid obesity: a systematic review and network meta-analysis.Endoscopy2020;52:940-54

[11] Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity.Gastrointest Endosc2013;78:530-5

[12] Fayad L,Schweitzer M.Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study.Gastrointest Endosc2019;89:782-8

[13] Vargas EJ,Gomez-Villa J.The effect of endoscopic sleeve gastroplasty on gastric emptying, motility, and hormones: a comparative prospective study.Gut2022;72:1073-80 PMCID:PMC10102256

[14] de Moura DTH, de Moura EGH, Thompson CC. Endoscopic sleeve gastroplasty: from whence we came and where we are going.World J Gastrointest Endosc2019;11:322-8 PMCID:PMC6556490

[15] Galvao Neto M,Campos JM. Endoluminal greater curvature plication - a case series. 2013. Available from: https://www.sages.org/meetings/annual-meeting/abstracts-archive/endoluminal-greater-curvature-plication-a-case-series/. [Last accessed on 20 Jun 2025]

[16] Beran A,Jaruvongvanich V.Comparative effectiveness and safety between endoscopic sleeve gastroplasty and laparoscopic sleeve gastrectomy: a meta-analysis of 6775 individuals with obesity.Obes Surg2022;32:3504-12

[17] Marincola G,Hassan C.Laparoscopic sleeve gastrectomy versus endoscopic sleeve gastroplasty: a systematic review and meta-analysis.Endosc Int Open2021;9:E87-95 PMCID:PMC7775813

[18] Sharaiha RZ,Kumar R.Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity.Clin Gastroenterol Hepatol2021;19:1051-7.e2

[19] Storm AC.Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures.Gastrointest Endosc2019;89:1139-40

[20] Endobariatric Procedural Reimbursement Guide. 2024 Coding & Payment Quick Reference. Available from: https://www.bostonscientific.com/content/dam/bostonscientific/Reimbursement/Gastroenterology/pdf/endobariatric-procedural-reimbursement-guide.pdf. [Last accessed on 20 Jun 2025]

[21] Jirapinyo P.Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video).Gastrointest Endosc2020;91:1388-94 PMCID:PMC8959111

[22] Reja D,Sarkar A.Endoscopic bariatrics: current therapies and future directions.Transl Gastroenterol Hepatol2022;7:21 PMCID:PMC9081914

[23] Miller K,Greve JW,Buchwald JN.MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose^SM vs. medical therapy.Obes Surg2017;27:310-22

[24] Alexandre F,Vannucci M.Endoscopic management of obesity: Impact of endoscopic sleeve gastroplasty on weight loss and co-morbidities at six months and one year.J Visc Surg2023;160:S38-46

[25] Singh S,Khan A.Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis.Surg Endosc2022;36:252-66 PMCID:PMC8389059

[26] Ker J,Bai Y,Lim T.Image thresholding improves 3-dimensional convolutional neural network diagnosis of different acute brain hemorrhages on computed tomography scans.Sensors2019;19:2167 PMCID:PMC6539746

[27] Espinós JC,Moragas G.Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure.Obes Surg2016;26:1081-9

[28] Sullivan S,Woodman G,De La Cruz-Muñoz N.Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial.Obesity2017;25:294-301

[29] Lopez-Nava G,Turró Arau R,Dayyeh BA.Modified primary obesity surgery endoluminal (POSE-2) procedure for the treatment of obesity.VideoGIE2020;5:91-3 PMCID:PMC7058528

[30] Lopez Nava G,Asokkumar R.Prospective multicenter study of the primary obesity surgery endoluminal (POSE 2.0) procedure for treatment of obesity.Clin Gastroenterol Hepatol2023;21:81-9.e4

[31] Jense MTF,Palm-Meinders IH.The POSE-2 procedure for people with obesity: a safe and effective treatment option.Obes Surg2024;34:3686-93 PMCID:PMC11464541

[32] Gys B,Lamme B.Endoscopic Gastric plication for morbid obesity: a systematic review and meta-analysis of published data over time.Obes Surg2019;29:3021-9

[33] Khan Z,Hajifathalian K.Efficacy of endoscopic interventions for the management of obesity: a meta-analysis to compare endoscopic sleeve gastroplasty, AspireAssist, and primary obesity surgery endolumenal.Obes Surg2019;29:2287-98

[34] Moreno C,Dugardeyn S.Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study.Endoscopy2008;40:406-13

[35] Leccesi L,De Gaetano A.Effects of transoral gastroplasty on glucose homeostasis in obese subjects.J Clin Endocrinol Metab2013;98:1901-10

[36] Familiari P,Bléro D.Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome.Gastrointest Endosc2011;74:1248-58

[37] Sullivan S,Thompson CC.Endoscopic bariatric and metabolic therapies: new and emerging technologies.Gastroenterology2017;152:1791-801

[38] Tawadros A,Kahaleh M.Overview of bariatric and metabolic endoscopy interventions.Ther Adv Gastrointest Endosc2020;13:2631774520935239 PMCID:PMC7488893

[39] Shenoy A.Advances in endobariatrics: past, present, and future.Gastroenterol Rep2023;11:goad043 PMCID:PMC10361810

[40] Tate CM.Intragastric balloon treatment for obesity: review of recent studies.Adv Ther2017;34:1859-75

[41] Qureshi H,Jovani M.Updates in endoscopic bariatric and metabolic therapies.J Clin Med2023;12:1126 PMCID:PMC9917553

[42] Abdulla M,AlQamish J.Overview on the endoscopic treatment for obesity: a review.World J Gastroenterol2023;29:5526-42 PMCID:PMC10642436

[43] Navez B,Michiels M.Surgical management of acute cholecystitis: results of a 2-year prospective multicenter survey in Belgium.Surg Endosc2012;26:2436-45

[44] Choi SJ.Various intragastric balloons under clinical investigation.Clin Endosc2018;51:407-15 PMCID:PMC6182294

[45] Sachdev P,Thomson M.Intragastric balloon as an adjunct to lifestyle programme in severely obese adolescents: impact on biomedical outcomes and skeletal health.Int J Obes2017;42:115-8 PMCID:PMC5763248

[46] FDA. Summary of safety and effectiveness data (SSED): ORBERATM intragastric balloon system. 2015. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034b.pdf. [Last accessed on 20 Jun 2025]

[47] ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee; Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies.Gastrointest Endosc2015;82:425-38.e5

[48] Kozłowska-Petriczko K,Wojciechowska K.The efficacy comparison of endoscopic bariatric therapies: 6-month versus 12-month intragastric balloon versus endoscopic sleeve gastroplasty.Obes Surg2022;33:498-505 PMCID:PMC9889469

[49] Suchartlikitwong S,Mingbunjerdsuk T.Usefulness of the ReShape intragastric balloon for obesity.Proc2019;32:192-5 PMCID:PMC6541059

[50] Abu Dayyeh BK,Rapaka B.Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.Lancet2021;398:1965-73

[51] Sullivan S,Woodman G.Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss.Surg Obes Relat Dis2018;14:1876-89

[52] Ienca R,Caballero A.The procedureless elipse gastric balloon program: multicenter experience in 1770 consecutive patients.Obes Surg2020;30:3354-62 PMCID:PMC7458897

[53] Kotinda APST,Ribeiro IB.Efficacy of intragastric balloons for weight loss in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials.Obes Surg2020;30:2743-53

[54] Popov VB,Schulman AR.The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis.Am J Gastroenterol2017;112:429-39

[55] Shah R,Abu Dayyeh BK,Murad MH.AGA technical review on intragastric balloons in the management of obesity.Gastroenterology2021;160:1811-30

[56] FDA. FDA In Brief: postmarket update on liquid-filled intragastric balloons. 2020. Available from: https://www.fda.gov/news-events/fda-brief/fda-brief-postmarket-update-liquid-filled-intragastric-balloons. [Last accessed on 20 Jun 2025]

[57] FDA. Summary of safety and effectiveness data (SSED). TransPyloric Shuttle/TransPyloric Shuttle delivery device. 2019. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034b.pdf. [Last accessed on 20 Jun 2025]

[58] Rothstein RI,Woodman GE.Randomized double-blind sham-controlled trial of a novel silicone-filled endoscopically placed device for weight loss.Tech Innov Gastrointest Endosc2024;26:21-9

[59] Orlandini B,Boškoski I,Costamagna G.Procedures and devices for bariatric and metabolic endoscopy.Ther Adv Gastrointest Endosc2020;13:2631774520925647 PMCID:PMC7271273

[60] Sauer N,Pezold J.A new endoscopically implantable device (satisphere) for treatment of obesity - efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 Levels.Obes Surg2013;23:1727-33

[61] Günthert SJ,Schröder O.Glycemic control and BMI changes after endoscopic implantation of a duodenojejunal bypass liner compared with laparoscopic Roux-en-Y gastric bypass surgery: a propensity score matching analysis.Surg Endosc2022;36:5979-85

[62] Igi WF,Matar A.Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control.Clin Endosc2024;57:309-16 PMCID:PMC11133994

[63] Yvamoto EY,Proença IM.The effectiveness and safety of the duodenal-jejunal bypass liner (DJBL) for the management of obesity and glycaemic control: a systematic review and meta-analysis of randomized controlled trials.Obes Surg2023;33:585-99

[64] Sandler BJ,Swain CP.One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity.Surg Endosc2015;29:3298-303

[65] Machytka E,Zonca P.Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes.Gastrointest Endosc2017;86:904-12

[66] Gagner M,Cadiere GB.Side-to-side magnetic duodeno-ileostomy in adults with severe obesity with or without type 2 diabetes: early outcomes with prior or concurrent sleeve gastrectomy.Surg Obes Relat Dis2024;20:341-52

[67] Van Baar ACG,Crenier L.Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study.Gut2019;69:295-303 PMCID:PMC6984054

[68] Haidry RJ,Galvao Neto MP.Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting.Gastrointest Endosc2019;90:673-81.e2

[69] Mingrone G,Devière J.Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial.Gut2021;71:254-64 PMCID:PMC8761999

[70] Aspire Bariatrics, Inc. AspireAssist instructions for use. 2015. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150024d.pdf. [Last accessed on 20 Jun 2025]

[71] Yoon JH.Current status of bariatric endoscopy in obesity control.Korean J Med2019;94:5-10

[72] Jirapinyo P,Saumoy M,Sullivan S.Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for aspiration therapy.Gastrointest Endosc2021;93:334-42.e1

[73] Waseem A,Maselli DB,Wooley C.Endoscopic removal of a weight-loss device with stoma closure using a tack-and-suture device.VideoGIE2023;8:441-2 PMCID:PMC10665149

[74] Köseoğlu HT,Akbay A.Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study.Ther Adv Gastrointest Endosc2024;17:26317745241233083 PMCID:PMC10929057

[75] Yen YA,Sung WW.Intragastric injection of botulinum toxin A for weight loss: a systematic review and meta-analysis of randomized controlled trials.J Gastroenterol Hepatol2022;37:983-92

[76] ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy; Ginsberg GG, Chand B, Cote GA, et al. A pathway to endoscopic bariatric therapies.Gastrointest Endosc2011;74:943-53

[77] Whaley CM,Kerber R,Kofner A. Prices paid to hospitals by private health plans: findings from round 4 of an employer-led transparency initiative. 2022. Available from: https://www.rand.org/pubs/research_reports/RRA1144-1.html. [Last accessed on 20 Jun 2025]

[78] AMA Category 1 CPT code for endoscopic sleeve gastroplasty (ESG). 2024. Available from: https://www.linkedin.com/posts/boston-scientific-endoscopy_endobariatrics-cptcode-medicalbillingandcoding-activity-7253049978745487361-9s0b/?utm_source=share&utm_medium=member_desktop. [Last accessed on 20 Jun 2025]